The crystal structure of a Fab fragment of an anti-17-estradiol antibody 57-2 was determined in the absence and presence of the steroid ligand, 17-estradiol (E2), at 2.5 and 2.15-Å resolutions, respectively. The antibody binds the steroid in a deep hydrophobic pocket formed at the interface between the variable domains. No major structural rearrangements take place upon ligand binding; however, a large part of the heavy chain variable domain near the binding pocket is unusually flexible and is partly stabilized when the steroid is bound. The nonpolar steroid skeleton of E2 is recognized by a number of hydrophobic interactions, whereas the two hydroxyl groups of E2 are hydrogen-bonded to the protein. Especially, the 17-hydroxyl group of E2 is recognized by an intricate hydrogen bonding network in which the 17-hydroxyl itself forms a rare four-center hydrogen bond with three polar amino acids; this hydrogen bonding arrangement accounts for the low cross-reactivity of the antibody with other estrogens such as estrone. The CDRH3 loop plays a prominent role in ligand binding. All the complementarity-determining regions of the light chain make direct contacts with the steroid, even CDRL2, which is rarely directly involved in the binding of haptens.The steroid 17-estradiol (E2) 1 is the major female sex hormone, and it has disseminated roles in a wide range of reproductive and nonreproductive physiological processes in different organs. E2 is the cell proliferation-promoting steroid hormone during the menstrual cycle, and it has known functions in bone metabolism and in the cardiovascular and central nervous systems. E2 is the most potent member of the family of estrogens, including estrone and estriol, and it binds tighter to the known human estrogen receptors (ER), ER␣ and ER, than other estrogens (1). In fertile women sera, the E2 concentrations range normally from 110 to 2200 pmol/liter, depending on the phase of the menstrual cycle (2), whereas in prepubertal and postmenopausal female sera, the concentrations are substantially lower. 17-estradiol is used as a drug in various hormone-dependent disorders; for example, supplementary E2 administered to postmenopausal women relieves postmenopausal symptoms, reverses urogenital atrophy, and increases bone mass. On the other hand, increased serum E2 levels have been linked with malignant/premalignant diseases such as breast cancer (3) and endometriosis (4).Immunoassays are routinely used to measure serum E2 levels. However, the generation of monoclonal antibodies with high enough affinity and specificity for steroid hormones has proven to be very difficult with the conventional hybridoma techniques. The conserved hydrophobic steroid skeleton of E2 with only two polar heavy atoms (3-and 17-hydroxyl groups) seems to be a particularly challenging target for the murine immune system, and the current E2 assays are based on polyclonal immunoglobulins from rabbit sera. However, the polyclonal antibodies have disadvantages compared with monoclonals. The most severe problem ...